Price
No data yet.
Social Signal Score
Analyst Ratings
20 analystsRevenue
$387.50M+3754.57%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Alan S. Bash
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,200
- Beta
- 0.40
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 3.74
Financials
Revenue
$387.50M+3754.6%Net Income
$33.20MEBITDA
$60.10MFree Cash Flow
$-41.49MEPS (diluted)
$0.18Shares Outstanding (diluted)
193.80M+93.4%Operating Expenses
$192.40MCash & Debt
$964.63MRevenue by Segment (annual)
$4.91MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.03B | $-296.80M | $-1.60 |
| 2024 | $627.24M | $-177.03M | $-0.97 |
| 2023 | $285.14M | $-518.25M | $-2.94 |
| 2022 | $117.00M | $-446.35M | $-2.81 |
| 2021 | $68.83M | $-403.58M | $-2.74 |
| 2020 | $75.00M | $-266.37M | $-2.57 |
| 2019 | $61.80M | $-101.59M | $-1.01 |
| 2018 | $49.13M | $-2.78M | $-0.03 |
| 2017 | $23.59M | $9.37M | $0.07 |
Valuation
LEGNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-62.50%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·11d ago·Positive
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM
View source ↗ - Newsglobenewswire.com·26d ago·Positive
…vidence and post-authorization safety study findings will also be presented BRIDGEWATER, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that data from CARTITUDE-2 and real-world evidence will be presented at the 23rd International Myeloma Society (IMS) Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland.
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript
View source ↗ - News247wallst.com·55d ago·Positive
Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus Shares of Legend Biotech (NASDAQ:LEGN | LEGN Price Prediction) are climbing 6% to $21.88 Tuesday midday after the company reported Q2 2026 results that paired a solid revenue beat with the first quarter of company-wide profitability in its history.
View source ↗ - Newsmarketbeat.com·56d ago·Neutral
Legend Biotech Q2 Earnings Call Highlights Legend Biotech NASDAQ: LEGN reported second-quarter 2026 results marked by continued global growth for CARVYKTI and the company's first quarter of company-wide profitability on both an IFRS and adjusted basis, management said during its earnings call.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $0.01 per share
Typical surprise +15.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$0.09 vs $0.12miss
- Tue, May 12$-0.15 vs $-0.02miss
- Tue, Mar 10$-0.08 vs $-0.17beat
- Wed, Nov 12$-0.11 vs $-0.13beat
- Mon, Aug 11$-0.34 vs $-0.11miss
- Tue, May 13$-0.07 vs $-0.23beat
Estimates and results for LEGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LEGN officers and directors.
- Bought
- —
- Sold
- $567k
0 trades
5 trades
- Sanders Corazon (corsee) D.sold
- Santos Carlos Esold
- Casey Patrick Johnsold
- Huang Yingsold
- Huang Yingsold
33 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LEGN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.